BioRem (CVE:BRM) Raised to Moderate Buy at Cormark

Cormark upgraded shares of BioRem (CVE:BRM) to a moderate buy rating in a research report sent to investors on Tuesday,Zacks.com reports.

BioRem Price Performance

BRM traded down C$0.02 during trading on Tuesday, reaching C$3.10. 21,060 shares of the company traded hands, compared to its average volume of 32,599. BioRem has a 12-month low of C$0.95 and a 12-month high of C$3.39. The firm has a fifty day simple moving average of C$2.82 and a 200 day simple moving average of C$2.40. The company has a debt-to-equity ratio of 48.97, a quick ratio of 1.08 and a current ratio of 1.57. The company has a market cap of C$48.67 million, a P/E ratio of 14.76 and a beta of 0.85.

Insider Buying and Selling

In other news, Director Derek Webb sold 120,000 shares of BioRem stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of C$2.93, for a total value of C$351,600.00. 1.90% of the stock is currently owned by company insiders.

About BioRem

BioRem Inc, a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). It offers biofilters for the removal of odors, H2S, VOCs, and HAPs; and biotrickling filters for applications of high levels of H2S or other water-soluble VOCs.